{
  "author": "cauchy-euler",
  "the_new_excerpt": "https://finance.yahoo.com/news/fda-approves-aurinia-pharmaceuticals-lupkynis-012400315.html\nand\nhttps://www.multivu.com/players/English/8811951-aurinia-pharmaceuticals-lupkynis-voclosporin/\n(Press Release)\n\n(NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the\nU.S. Food and…",
  "original_created_utc": 1611373113,
  "localize": [
    {
      "locale": "zh",
      "the_new_excerpt": "https://finance.yahoo.com/news/fda-approves-aurinia-pharmaceuticals-lupkynis-012400315.html\n和\nhttps://www.multivu.com/players/English/8811951-aurinia-pharmaceuticals-lupkynis-voclosporin/\n(新闻稿)\n\n(纳斯达克：AUPH / 多伦多证券交易所：AUP)(\"Aurinia \"或 \"公司\")今天宣布。\n美国食品和...",
      "title": "AUPH的LUPKYNIS小时后获得FDA批准"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": "https://finance.yahoo.com/news/fda-approves-aurinia-pharmaceuticals-lupkynis-012400315.html\n和\nhttps://www.multivu.com/players/English/8811951-aurinia-pharmaceuticals-lupkynis-voclosporin/\n(新聞稿)\n\n(納斯達克：AUPH / 多倫多證券交易所：AUP)(\"Aurinia \"或 \"公司\")今天宣佈。\n美國食品和...",
      "title": "AUPH的LUPKYNIS小時後獲得FDA批准"
    }
  ],
  "title": "AUPH receives FDA approval for LUPKYNIS after hours",
  "created_utc": 1611433062,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><p><a href=\"https://finance.yahoo.com/news/fda-approves-aurinia-pharmaceuticals-lupkynis-012400315.html\">https://finance.yahoo.com/news/fda-approves-aurinia-pharmaceuticals-lupkynis-012400315.html</a> and \n<a href=\"https://www.multivu.com/players/English/8811951-aurinia-pharmaceuticals-lupkynis-voclosporin/\">https://www.multivu.com/players/English/8811951-aurinia-pharmaceuticals-lupkynis-voclosporin/</a> (Press Release)</p>\n\n<p>(NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN). LUPKYNIS is the first FDA-approved oral therapy for LN. LN causes irreversible kidney damage and significantly increases the risk of kidney failure, cardiac events, and death. It is one of the most serious and common complications of the autoimmune disease systemic lupus erythematosus (SLE). LUPKYNIS is now available to patients in the United States (U.S.).</p>\n\n<p>Aurinia will host a conference call and webcast to discuss the approval of LUPKYNIS on Monday, January 25, 2021 at 8:30 a.m. ET. The webcast can be accessed on the investor section of the Aurinia website at <a href=\"http://www.auriniapharma.com\">www.auriniapharma.com</a>. </p>\n\n<p>Good news to all the AUPH stockholders out there. Are you selling or holding for a potential buyout?</p>\n</div><!-- SC_ON -->",
  "score": 45,
  "permalink": "/r/stocks/comments/l34bqj/auph_receives_fda_approval_for_lupkynis_after/",
  "subreddit": "stocks",
  "id": "l34bqj",
  "is_self": true,
  "media": null,
  "is_video": false
}